CD40 and neoplasm: We attempted to determine whether leveraging the immune cell changes in the TME mediated by erlotinib with an immunotherapeutic agent like anti-PD-1 or an agonistic CD40 antibody could further stimulate the immune system to exert anti-tumor effects.